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We report an unusual case of a Duchenne Muscular Dystrophy(DMD) patient who initiated a
restless leg syndrome after the use of amytriptiline. The prescription and use of this
medication for patients with persistent neuropathic pain is relatively common, especially for
patients with DMD. Normally, this medication is well tolerated, however, we now report the
occurrence of an induction or intensiﬁcation of a restless leg syndrome case in a young
patient with DMD, treated with amytriptiline for his chronic pain.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Duchenne Muscular Dystrophy (DMD) is a neuromuscular
disease linked to the X chromosome which afﬂicts 1 in every
3500 born boys. DMD is caused by a mutation on the dystro-
phin gene at locus Xp.21, leading to dystrophin absence or a
production defect in the muscles. Affected individuals demon-
strate progressive loss of muscle tone and respiratory, cardiac
and orthopedic impairment. Loss of walking capacity usually
occurs around 9–11 years of age and death between 20 and 30
years of age [1]. Neuromuscular diseases, in general, may be
developed by chronic pain as a result of contractures, defor-
mities and immobility, with great impact on the quality of lifeep. Production and Hosti
licenses/by-nc-nd/3.0/).
5; fax: þ55 11 5572 5092.
m, mandersen@unifesp.[2]. Pharmacological treatment with amytriptiline chloride
constitutes one of the multimodal aspects of intervention for
the pain treatment in patients with neuromuscular diseases
[3]. There is a possible association between tricyclic antide-
pressants and the restless leg syndrome (RLS) [4].
We presently report a case where a patient with diagnostic
of DMD demonstrated a marked worsening of his RLS,
associated with the use of amytriptiline.
2. Case report
Male patient with 27 years of age, with diagnostic of Duch-
enne Muscular Dystrophy at the age of 7 years. Beginning ofng by Elsevier B.V. This is an open access article under the CC BY-
br (M.L. Andersen).
Table 1 – Probability scale of DAR of Naranjo et al. [11].
Criteria for the deﬁnition of causal relationship Yes No Undetermined
Are there conclusive reports about this reaction? 0
Has the clinical event appeared after the administration of the suspected drug? þ2
Has the reaction disappeared when the suspected drug was discontinued or when the speciﬁc antagonist
was administered?
þ1
Has the reaction reappeared when the drug was reinstated? 0
Are there alternative causes (other than the drug) which could provoke that reaction? þ2
Has the reaction reappeared when a placebo is given? 0
Has the drug been detected in the bloodstream or in other biological ﬂuids in well known toxic
concentrations?
0
Does the reaction increases with the increase of the drug dosage or becomes less severe with drug
reduction?
þ1
Does the patient have a history of similar reaction to the same drug or a similar one in some previous
exposure?
0
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 7 8 – 1 8 0 179symptoms at the age of 6, with myopathic walk and difﬁculty
in climbing stairs. Loss of walking ability at 10. With 19 years
old, evolved to alveolar hypoventilation syndrome and
the need of ventilatory support with non-invasive mechan-
ical ventilation. At this age, the patient already demonstrated
movement restriction, with global tetraparesis. At the age
of 23, initiated with diffuse and continuous chronic pain,
worsening of passive limb movements and daily chronic
migraine resulted from analgesic abuse. We then initiated
treatment with a tricyclic antidepressant (amytriptiline chlor-
ide 25 mg/night). After a few days of therapy the patient
referred a feeling of undetermined discomfort in his inferior
limbs, beginning every day in the evening, with intense will
to move his legs, only relieved by passive movement of
his legs (done by his caretaker since he was incapable of
doing it himself). The phenomenon lasted for 2 h, making it
difﬁcult to sleep and with spontaneous remission. The
patient had demonstrated similar symptoms previously
although with less intensity, duration and frequency. There
was no evidence of periodic limb movements (patient
with global tetraparesis and motor strength grade 1, making
it impossible to move the limbs), peripheral neuropathy,
spinal radiculopathy or other associated conditions. He had
positive familiar history (mother refers some characteristi-
cally similar episodes, not related to any drug usage, with low
frequency and intensity). Blood tests were considered nor-
mal. With the interruption of the medication, after approxi-
mately 30 days, the patient showed marked improvement of
this condition, with decrease of the episodes and symptoms,
maintaining its eventual frequency. The punctuation of the
Naranjo and cols Drug Adverse Reaction (DAR) probability
scale (1981) was of 6 points, indicating a probable side effect
of the drug (Table 1).3. Discussion
Patients with DMD show high risk for the development of
respiratory disorders related with sleep, mainly the sleep
obstructive apnea syndrome and alveolar hypoventilation [5].
Other sleep disorders include difﬁculty in initiating and
maintaining sleep. Many patients show important sleep
fragmentation with frequent awakenings for decubitalchanges (by the caretakers) due to pain or discomfort [6].
There is very little information about movement disturbances
during sleep in these patients.
RLS is a motor-sensitive disorder related to sleep, char-
acterized by discomforting or painful paresthetic sensations
in the legs, between the ankle and the knee at rest, accom-
panied by the intense need to move the affected limbs. The
RLS physiopathology is still not established; however, there
are some hypothesis related to the mechanisms of central
and peripheral nervous system processing and some ele-
ments of the motor system, as well as the dopaminergic and
iron metabolisms systems. RLS may be classiﬁed as idio-
pathic, genetic with a dominant autosomic heritage pattern,
or secondary to a subjacent clinical condition. The RLS
diagnosis is exclusively clinical, obeying the minimal criteria
in accordance to the International Restless Legs Syndrome
Study Group – IRLSSG and of the International Sleep Dis-
orders Classiﬁcation of 2005, being essential criteria the
following: irresistible and intense need to move the legs,
generally accompanied by discomfort or inconvenience; the
symptoms worsen or are exclusively present at rest or during
inactivity, sitting or laying down; the symptoms are alle-
viated totally or partially with movement; symptoms worsen
or occur exclusively at night. The described symptoms are
not best explained by any other diseases of conditions.
The support criteria for diagnostic of RLS are: elevated index
of periodic leg movement during sleep; positive familiar
history; therapeutic response to dopaminergic agents; clinical
course [7,8].
Several medications do appear to possess the potential to
induce or intensify RLS, including antiemetics, antipsychotics
and antidepressants (tricyclic, serotonin reuptake inhibitors,
selective noradrenergic–serotonergics) [9]. Amytriptiline chlor-
ide is a potent antidepressant with sedative and anticholiner-
gic properties, acting by inhibiting the membrane pump
mechanism responsible for the norepinephrine and serotonin
uptake by adrenergic and serotonergic neurons. It also shows,
in less proportion, activity upon the blockage of dopamine
reuptake, with possible psychomotor activation [12], this
action being possibly related to the development of RLS.
It is considered one of the drugs of ﬁrst choice for the
treatment of chronic pain, acting upon different nociceptive
mechanisms. Some of its side effects include excessive
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 7 8 – 1 8 0180sleepiness, insomnia, nightmares, paresthesias and extrapir-
amidal symptoms [3]. These effects might result in sleep
disturbances.
Establishing a relationship cause/effect between a clinical
event and the use of a medication presents intrinsic difﬁcul-
ties, bearing in mind inespeciﬁcity and the superimposition
of several factors. One way of establishing a causal relation-
ship with higher security is the use of algorithms with
diagnostic criteria for DAR, such as the probability scale of
DAR according to Naranjo et al. [11]. In this system, a
punctuation between 5 and 8 indicates a probable causality,
establishing that the reaction follows a reasonable chronolo-
gical sequence from the initial administration of the drug,
with a previously know response and which cannot be totally
explained by the clinical course of the patient [10,11].
The patient here described demonstrated 4 of the 5
essential criteria for RLS and positive familiar history, asso-
ciated with a relatively high probability of causality with a
drug side effect. The criterion related to the beginning of the
symptoms at rest or during inactivity periods, could not be
evaluated or observed, due to the patient's global tetraparesis
condition, making him totally restricted to bed during day
and night timeframes. Considering the relaxation concept
and incorporating the level of activity of the central nervous
system with the decrease of the vigil level, then we deter-
mined that the patient really demonstrated all the essential
criteria, once the symptoms only arose when the patient was
beginning to sleep. This case describes a probable and rare
side effect of amytriptiline related to sleep in a patient
with DMD.4. Conclusion
We point out the importance of this association and identi-
ﬁcation due to its great discomfort described by the patient.
This clinical symptom is of major importance since the
patient with DMD is incapacitated of own motor mobility as
a way to relieve his condition, therefore leading to a physical
and emotional distress. In our knowledge, this is the ﬁrst
description of such association between tricyclic antidepres-
sant and RLS in DMD. We point out that the association of
medication with RLS is described in small series and case
reports and the presently here described association must be
interpreted with caution and be conﬁrmed in other more
structured studies in the future.Acknowledgements
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